Le Lézard
Classified in: Health
Subject: SVY

Global Allergy Immunotherapies Markets, 2018-2019 & 2024: Demand for Sophisticated and Long-Term Treatment Options is Increasing


DUBLIN, Aug. 23, 2019 /PRNewswire/ -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global allergy immunotherapies market was worth US$ 1.6 Billion in 2018

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system's response by gradually increasing the doses of the allergen.

Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient's life.

In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world.

Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.

Looking forward, the market to reach a value of US$ 2.4 Billion by 2024, registering a CAGR of around 7% during 2019-2024.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Allergy Immunotherapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Treatment Type
5.4 Market Breakup by Allergy Type
5.5 Market Breakup by Distribution Channel
5.6 Market Breakup by Region
5.7 Market Forecast

6 Market Breakup by Treatment Type
6.1 Subcutaneous Immunotherapy (SCIT)
6.2 Sublingual Immunotherapy (SLIT)

7 Market Breakup by Allergy Type
7.1 Allergic Rhinitis
7.2 Asthma
7.3 Food Allergy
7.4 Venom Allergy
7.5 Others

8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.2 Retail Pharmacy
8.3 Online Pharmacy

9 Market Breakup by Region

10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis
13.1 Price Indicators
13.2 Price Structure
13.3 Margin Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 ALK-Abello A/S
14.3.2 Allergy Therapeutics
14.3.3 Stallergenes Greer
14.3.4 HAL Allergy Group
14.3.5 DBV Technologies
14.3.6 Merck Group
14.3.7 Aimmune Therapeutics
14.3.8 Circassia Pharmaceuticals
14.3.9 Anergis SA
14.3.10 Biomay AG

For more information about this report visit https://www.researchandmarkets.com/r/oqvzeb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 04:00
A bioactive polymer-ceramic composite for fixing implants and restoring bone defects in the skull was developed by an international group of materials scientists from the NUST MISIS Center for Composite Materials. An innovative composition of the...

at 03:52
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first half ended 30 June 2020. The full report can be accessed by clicking here. Operational Highlights for...

at 03:00
COVID-19 has accelerated the need for food companies to build more resilient and transparent supply chains to cope with the challenges from an ever evolving marketplace. It is now more urgent than ever to have the proper framework that would allow...

at 03:00
The list of reviewed and approved NJ Top Docs at Kayal Orthopaedic Center, PC is continuously growing. Kayal Orthopaedic Center is home to an elite team of surgeons who are fully committed to skillful, restorative patient care. Patients in Franklin...

at 03:00
HashCash Consultants has partnered with a leading manufacturer in the US to help them streamline and facilitate the production and supply of PPE kits across various channels to keep unsaturated availability in the market. In the wake of the pandemic,...

at 02:51
Isofol Medical AB (publ) ("Isofol"), has today announced that it entered into a license agreement with Solasia Pharma K.K ("Solasia") (TSE: 4597), to develop and commercialize Isofol's proprietary late-stage drug candidate arfolitixorin in Japan. In...



News published on 23 august 2019 at 11:00 and distributed by: